The Muscle RING-finger protein-1 (MuRF1), encoded by the *TRIM63* gene, is a muscle-specific E3 ubiquitin ligase that plays a critical role in protein ubiquitination and degradation via the ubiquitin-proteasome system (UPS). Primarily expressed in skeletal and cardiac muscles, MuRF1 is a key regulator of muscle atrophy under conditions such as denervation, fasting, cancer cachexia, and sepsis. It targets structural proteins like titin, myosin heavy chains, and troponin I for degradation, leading to muscle wasting. Research on MuRF1 has surged due to its involvement in pathological and physiological muscle remodeling, making it a biomarker for muscle atrophy and a therapeutic target for diseases like muscular dystrophy, heart failure, and age-related sarcopenia.
MuRF1 antibodies are essential tools for detecting and quantifying MuRF1 expression in research. These antibodies, often developed in rabbits or mice, are validated for applications including Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and immunoprecipitation (IP). Specificity and sensitivity vary among commercial antibodies, requiring careful validation using knockout controls. MuRF1 antibodies have enabled discoveries in molecular pathways linking inflammation, oxidative stress, and hormonal signaling to muscle degradation. Commercially available from suppliers like Cell Signaling Technology, Abcam, and Santa Cruz Biotechnology, these antibodies continue to support studies aiming to modulate MuRF1 activity to counteract muscle wasting in clinical settings.